期刊
JOURNAL OF CONTROLLED RELEASE
卷 219, 期 -, 页码 181-191出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.10.009
关键词
Oncolytic adenovirus; Clinical trials; Cancer gene therapy; Oncolytic Ad/polymer hybrid vector; Active targeting; Tumor microenvironment targeting; Systemic administration
资金
- National Research Foundation of Korea [2010-0029220, 2013M3A9D3045879]
- National Institutes of Health, USA [CA177932]
- National Research Foundation of Korea [2010-0029220, 2013M3A9D3045879] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据